Product Description
Orally available, multi-targeted CLK inhibitor BH-30236 is designed to selectively modulate aberrant alternative splicing in cancerous tissue and shut down cancer’s ability to use off-target resistance mechanisms. We aim for BH-30236 to be applied to hematologic cancers and solid tumors. The first indications for its use are in treating adult AML and higher-risk myelodysplastic syndrome (HR-MDS). (Sourced from: https://bhtherapeutics.com/pipeline/bh-30236/)
Mechanisms of Action: CLK Inhibitor
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BlossomHill Therapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Acute Myeloid Leukemia|Myelodysplastic Syndrome|Preleukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| HR-MDS | P1 |
Recruiting |
Preleukemia|Acute Myeloid Leukemia|Myelodysplastic Syndrome |
2026-06-01 |